Please login to the form below

Not currently logged in
Email:
Password:

Cytos Biotechnology

This page shows the latest Cytos Biotechnology news and features for those working in and with pharma, biotech and healthcare.

Alzheimer's disease pipeline takes multiple hits

Alzheimer's disease pipeline takes multiple hits

modulator EVP 0962 (EnVivo Pharmaceuticals); the metal protein-attenuating compound called PBT 2 (Prana Biotechnology); and ELND 005 (Speranza Therapeutics). ... Phase II agents include vanutide cridificar (Elan, Pfizer, Janssen Alzheimer Immunotherapy),

Latest news

  • Kicking the habit

    Vaccination route. It appears that vaccination could also be an option in modern day smoking cessation therapy, of which the most advanced are Nabi Biopharmaceuticals' NicVAX and Cytos Biotechnology's ... Cytos has completed a phase II study in 341

  • Silent, yet deadly

    CYT 006 AngQb, from Cytos Biotechnology, is another new therapeutic vaccine in development.

  • Deals in development

    been evaluated in patients with lung cancer, prostate cancer and ovarian cancer; and Cytos Biotechnology's NIC-002 ó a therapeutic vaccine for the potential treatment of nicotine dependency. ... The deal that brought NIC-002 to the Novartis portfolio

  • News in Brief, May 30, 2007

    Cytos reports results from a phase I/IIa psoriasis vaccine study. Switzerland-headquartered Cytos Biotechnology has reported results from a placebo-controlled, double-blind combined phase I/IIa study with ... Cangene manufactures VIG in its Winnipeg

  • News in brief, May 02, 2007

    Cytos Biotechnology enters nicotine vaccine agreement with Novartis. Swiss biotechnology company, Cytos, has entered into an exclusive global commercial license agreement with Novartis, to develop, manufacture and commercialise CYT002-NicQb, a

More from news
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    Exclusive commercial licence. 165. Cytos Biotechnology. Checkmate Pharmaceuticals. CYT 003 and VLP [virus like particle] platform in oncology.

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Corporate acquisition. 545. Cytos Biotechnology/ OnCore. Access to virus like particle (VLP) platform for the treatment and prevention of hepatitis B with an option to other viral diseases.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics